COVID-19 has forced the life science industry to embrace digital engagement with HCPs at scale. But, remote detailing is not going to be successful unless pharma can offer value, according to OKRA Technologies.
Those pesky ones and zeros lurked behind virtually every key trend in pharma marketing in 2019, and their influence will only grow in 2020.
In essence, we all want those boots on the ground to drive commercial value. Yet, not every high-priced pair of shoes delivers the desired ROI. Physician access time or practice location, and position of the brand in its life cycle, often make the cost of deploying a traditional field rep undesirable. Yet, many brands benefit from a personal visit to the office.
Physicians, residents and students expect that almost a third of their duties could be automated by technology in the next 20 years, according to the results of a national survey commissioned by Stanford Medicine and published in January.
The first of the Insys Therapeutics executives found guilty of violating the Racketeer Influenced and Corrupt Organizations (RICO) Act in May 2019 was sentenced to 33 months in federal prison.
French researchers are developing what they say is the most powerful Magnetic Resonance Imaging (MRI) scanner in the world, which will use a supermagnet the weight of a blue whale and should allow earlier diagnosis of diseases such as Parkinson’s.
Blue Cross Blue Shield of Massachusetts’ Alternative Quality Contract slowed the rate of medical spending growth by up to 12 percent while improving patient care over the course of eight years, according to a Harvard Medical School study published in the New England Journal of Medicine.
David Lickrish – president, founder and chief executive officer of Highland Therapeutics and Ironshore Therapeutics – spoke with BioSpace about the companies’ Jornay PM (methylphenidate HCL Extended-Release CLL Capsules) and how the new drug fits into the overall ADHD therapeutic market.
Almost 15,000 physicians, scientists, health-care professionals and industry representatives from around the globe presented research, treatment recommendations and advances toward a diabetes cure at the American Diabetes Association (ADA)’s 79th Scientific Sessions in San Francisco.
Working in the rare disease space has never been more rewarding than it is today. Technology is turning what was once thought to be impossible into actual, tangible realities for physicians, patients, and families. There are many exciting advancements happening now – in real time – and even more on the horizon that demand our attention and advocacy to help bring them to light.
